ArrowUP
Polyprenols in diseases of liver and central nervous system

Despite the fact that polyprenols can be widely used for the treatment of diseases associated with viral, bacterial and fungal infections, inflammations and other immune conditions, this article presents new pre-clinical and clinical effects of polyprenols in diseases of the liver and central nervous system. The article was published in English in the journal of "Experimental and Clinical Gastroenterology" 11\2016, author – V. S. Sultanov (Prenolica LTD, Australia), Candidate of Chemical Sciences.

The pathway of synthesis of isoprenoids in mammals (also known as the mevalonate pathway) is fundamental to the metabolism and health of the organism, and such compounds as cholesterol (sterol isoprenoid), ubiquinone (coenzyme Q) and dolichol (non-sterol isoprenoid) are of great importance for the biology and physiology of mammals. The impact on the pathway of exchange of isoprenoids leads to new therapeutic opportunities that are applicable to a wide range of different pathological conditions. Plant polyprenols are active molecules that affect the pathway of exchange of isoprenoids. Side effects have never been recorded in the use of our polyprenols of pharmaceutical quality. Statins and bisphosphonates also affect this pathway of exchange, but they have numerous side effects. Despite the fact that polyprenols can be widely used for the treatment of diseases associated with viral, bacterial and fungal infections, inflammations and other immune conditions, this article presents new pre-clinical and clinical effects of polyprenols in diseases of the liver and central nervous system. Recent preclinical trials have shown that the treatment with polyprenols produced from conifer needles has a variety of neurological and cognitive effects, including improvement of the cognitive function in rats with Alzheimer's disease and restoration of a healthy level of myelination in mice on the model of multiple sclerosis. Earlier clinical studies showed that the treatment with polyprenols improves levels of antioxidants in persons with diabetes mellitus, as well as improves the liver function in patients undergoing chemotherapy. Polyprenols also have a positive impact on the electroencephalogram in persons with Alzheimer's disease and alcoholic liver cirrhosis and significantly reduce symptoms of depression in patients.

The results provide a basis for more extensive clinical research and indicate that polyprenols are a valuable clinical "instrument" in the treatment of a variety of neurological and hepatological diseases.

* A polyprenolic preparation of Ropren was used the study, which is a pure concentrate of polyprenols (the total fraction is 95%). The text of the study is provided by courtesy of Solagran.

Original (pdf)